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ABSTRACT 
Objective: The objective of this selective EBM review is to determine whether “TNF- 
inhibitors Infliximab and Certolizumab pegol are effective in treating adults with Psoriatic 
Arthritis (PsA) or PsA patients who have previously failed disease-modifying anti-rheumatic 
drug (DMARD) therapy 
 
Study Design: Review of three randomized, double-blind, placebo controlled clinical trials 
published after 2006. 
Data sources: Three articles were found on PubMed and chosen based upon patient oriented 
outcomes relevant to the patient population. The population study was adults with psoriatic 
arthritis (PsA) and patients with PsA who failed prior DMARD therapy. Infliximab and 
certolizumab pegol were analyzed for treatment efficacy. 
Outcomes: There were three outcomes measured, looking at different angles to assess the 
efficacy of infliximab and/or certolizumab pegol. ACR 20 response was the endpoint chosen in 
one study, household productivity was chosen for another study, and PASI 75 response was the 
primary outcome in the last study. 
Results: Atteno et al2 showed a statistically significant ACR 20 response in patients treated with 
infliximab. Kavanagh et al7 demonstrated a statistically significant increase in household 
productivity in patients treated with certolizumab pegol. Torii et al evidenced a statistically 
significant PASI 75 response in patients treated with infliximab.  
Conclusions: The evidence shows that TNF- inhibitors infliximab and certolizumab pegol are 
effective in treating adults with psoriatic arthritis as well as PsA patients with prior failure of 
DMARD therapy. They have been shown in these trials to effectively reduce symptoms of 
arthritis and psoriasis, and improve quality of life with minimal adverse events compared to 
control. Prompt treatment of PsA with TNF- inhibitors may impact the disease progression and 
joint destruction in patients with PsA. 
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INTRODUCTION 
Psoriatic arthritis is a spondyloarthropathy occurring in patients with clinical skin or nail 
psoriasis which leads to progressive and severe destruction of joints. Progressive damage is seen 
within 2 years by radiographic evidence. Thus, prompt treatment is necessary to control the 
symptoms of inflammation and progressive damage of articular surfaces.1 This paper evaluates 
three randomized control trials comparing the effectiveness of infliximab and certolizumab pegol 
for the treatment of Psoriatic arthritis.  
The estimated incidence is approximately 6 per 100,000 per year with a prevalence of 1 
to 2 per 1000 in the general population.2 The direct estimate for the annual health care costs of 
PsA in the US is approximately $1.9 billion, with a substantial increase in cost as the disease 
progresses.3 In one study, patients with PsA made 20.3 visits to a general practitioner each year 
and 3.9 visits to a rheumatologist.3 The precise etiology has not been identified, however, it is 
known that PsA has a strong genetic component, with approximately 40% of patients with a 
positive family history of the disease.4 Tumor necrosis factor (TNF)-, a pro-inflammatory 
cytokine, is thought to have a role in the pathogenesis of PsA.1 Elevated levels of this cytokine 
has been reported in psoriatic skin lesions as well as in synovial fluid of PsA patients. 
Interestingly, TNF- concentration has also been seen to decrease in correlation with increase in 
therapeutic benefit.5 
The current goal of treatment is to reduce inflammation and prevent or prolong eventual 
joint destruction.6 Choice of initial drug depends on the severity of symptoms and joint disease. 
Treatment generally consists of non-steroidal anti-inflammatory drugs (NSAIDs), 
corticosteroids, or non-biologic DMARDS such as methotrexate or leflunomide for more 
moderate disease. However, these drugs produce moderate benefits at best, and the use of TNF-  
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inhibitors has generated increased interest as a therapeutic alternative.1 In addition, the 
conventional therapies for the treatment of psoriasis in this patient population presents issues of 
insufficient responses, adverse drug reactions, and recurrence after discontinuation. A novel drug 
that is effective for psoriasis as well as arthritis is needed.5 The treatments being proposed are 
Tumor necrosis factor (TNF) alpha inhibitors, namely infliximab and certolizumab pegol. These 
agents have been shown to be effective, and are an important treatment option for patients, 
especially for those who have been refractory to other treatments. 
OBJECTIVE 
The objective of this selective EBM review is to determine whether “TNF- inhibitors 
Infliximab and Certolizumab pegol are effective in treating adults with Psoriatic Arthritis (PsA) 
or PsA patients who have previously failed disease-modifying anti-rheumatic drug (DMARD) 
therapy.” 
METHODS 
 During the process of this review, three randomized control trials (RCT) were selected. 
The search criteria consisted of an adult population with or without failure of standard DMARD 
therapy, infliximab and/or certolizumab pegol as interventions, and outcomes that were patient-
oriented. The outcomes chosen were the Psoriasis Area and Severity Index (PASI), Household 
productivity, and American College of Radiology (ACR) response. The comparisons were 
chosen against a placebo and from other biologic DMARDs.  
 The articles were researched through PubMed, using the keywords “TNF-a inhibitors,” 
“infliximab,” “certolizumab pegol,” and “Psoriatic arthritis.” All three articles chosen were based 
on the relevance to the desired patient population and intervention with patient-oriented 
outcomes. They were published in English in peer-reviewed journals. Regarding inclusion 
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criteria, the articles were randomized controlled trials (RCTs), were relevant, and were published 
within the last 7 years. Non-randomized trials were excluded within reason as well as studies that 
looked at disease oriented outcomes. The reported statistics included relative benefit increase 
(RBI), absolute benefit increase (ABI), numbers needed to treat (NNT), and p-value. A summary 
of the three articles is provided in table 1. 
 
Table 1: Demographics and Characteristics of Included studies 
Study Type # Pts. Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Atteno1 
(2010) 
RCT 100 36-61 Patients 
older than 
18 years old 
with active 
PsA and 
with 
inadequate 
response to 
DMARD 
therapy 
Prior use of 
TNF 
inhibitors, 
usage of 
more than 
10mg of 
prednisone 
daily, 
variation of 
dosage on 
NSAIDs or 
prednisone 
within 2 
weeks of 
enrollment 
0 Infliximab 
5mg/kg every 
6 weeks 
Kavanagh7 
(2015) 
RCT 409 35-60 Patients 18 
or older 
with a 
diagnosis 
greater than 
6 months 
with active 
skin lesions 
or a 
documented 
history of 
psoriasis, 
prior 
treatment 
failure with 
DMARD 
History of 
inflammatory 
arthritis other 
than PsA or 
secondary 
condition 
significant 
enough to 
interfere with 
evaluation, 
prior 
treatment 
with more 
than two 
biologics or 
primary 
failure to a 
40 Certolizumab 
400mg at 
weeks 0,2, 4 
followed by 
either 200mg 
every 2 weeks 
or 400mg 
every 4 weeks 
subcutaneously 
with a blinded, 
pre-filled 
syringe 
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TNF 
inhibitor. 
Torii5 
(2010) 
RCT 54 30-59 PsA 
patients 
who have 
had 
moderate to 
severe 
plaque 
psoriasis 
for at least 
6 months 
History of 
serious 
infection, 
active TB, 
conventional 
therapy 
within 2 
weeks before 
enrollment 
7 Induction 
therapy with 
Infliximab 
5mg/kg IV  
 
 
OUTCOMES MEASURED 
 
 Three outcomes were measured, looking from different perspectives to assess the efficacy 
of infliximab and/or certolizumab pegol. Atteno et al1 looked at the American College of 
Radiology Response (ACR) which accounts for Psoriasis Severity Index (PASI), health 
assessment questionnaire (HAQ), and tender and swollen joints. Kavanagh et al7 looked at 
household productivity, measured by patient survey of symptoms affecting activity. The survey 
asked every patient the same 5 questions relating to their productivity at home, or lack thereof 
due to their arthritis: days where no work was performed at home due to arthritis; days where 
household productivity was reduced by >50%; days with outside hired help due to arthritis; days 
with leisure activities missed due to arthritis; and level of arthritis interference with household 
productivity. Torii et al5 used the Psoriasis Area and Severity Index (PASI), a standardized 
system based on findings of erythema, induration, and scaling on the head, trunk, and limbs 
determined on physical exam.  
RESULTS 
 Three randomized control trials were analyzed in this review. All studies evaluated the 
treatment efficacy of infiliximab (INF) or certolizumab pegol (CZP) over the course of months 
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for patients greater than 18 years with psoriatic arthritis. Patients who have received prior 
treatments with TNF- inhibitors were excluded from the studies.  
 Atteno et al1 compared the effectiveness of infliximab (INF) to other TNF- inhibitors 
etanercept (ETN) and adalimumab in 100 patients with PsA with inadequate response to a prior 
DMARD. These patients routinely attended the Psoriatic Arthritis Clinic at the University of 
Frederico II. The study excluded patients with previous usage of TNF- inhibitors, and patients 
who took NSAIDs within 2 weeks and prednisone within 4 weeks, presumably to ensure no 
overlap between the anti-inflammatory effects of these drugs with the drug of study. Etanercept 
was chosen as the comparison medicine. The data was presented as dichotomous and all patients 
were followed with an intention to treat analysis. All patients were randomly given INF 5mg/kg 
every 6-8 weeks or ETN 50mg weekly. Effectiveness was defined as percentage of ACR 20 
responders and as clinical remission. Table 2 demonstrates the status of the patient at the 1 year 
follow up. Patients treated with INF had higher HAQ scores (p=0.03), and less swollen joints 
(p<0.01) than patients treated with ETN at baseline. Additionally, patients receiving INF showed 
greater improvements of psoriatic rash when compared to ETN (p <0.01). ACR response rates 
were 72% of ETN and 75% of INH. Adverse events, though considered mild to moderate, 
occurred in 23% of INF patients and 17% of ETN patients (p<0.01). There were only two serious 
adverse effects in the INH group thought to be drug related, pneumonitis and thrombocytopenia. 
It should be noted that all TNF- inhibitors effectively controlled signs and symptoms of PsA. 
Comparing INH to ETN, the relative benefit increase (RBI) was 0.041 and the absolute benefit 
increase (ABI) was 0.03. The numbers of patients needed to treat (NNT) to achieve desired 
clinical response was 34. 
Table 2: Clinical and therapeutic characteristics of patients after 1 year 
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 Overall 
(n=100) 
Etanercept 
(n=36) 
Adalimumab 
(n=34) 
Infliximab 
(n=30) 
p value 
PASI 0.6 (2) 2 (4.4) 0.1 (1.9) 0 (1) <0.01 
HAQ 0.1 (0.1) 0.1 (0) 0.1 (0.2) 0.1 (0) 0.60 
Tender joints 1 (1) 1 (1) 1 (2) 1 (1.8) 0.12 
Swollen 
joints 
0 (1) 0 (1) 0.5 (1) 1 (1) 0.23 
 
 Kavanagh et al7 randomized 409 patients age 18 and older who have had PsA for greater 
than 6 months and prior failure to DMARD therapy. Active psoriatic lesions and increased 
inflammatory markers such as erythrocyte sedimentation rate and C-reactive protein above upper 
limits were necessary for consideration of candidates in the trial. Prior treatment with TNF-  
inhibitor was allowed in up to 40% of patients. Patients with a secondary non-inflammatory 
arthritis were excluded due to possible interference with evaluation. Patients were given a 
loading dose of certolizumab (CZP) 400mg followed by CZP 200mg every 2 weeks or 400mg 
every 4 weeks. Results were measured by a Work Production Survey which was taken at 
baseline and every 4 weeks. 90% of the patients completed the 24-week placebo-control, and 
43% of the patients who received placebo underwent mandatory escape and were re-randomized. 
Patients treated with either dose of CZP reported improvements in household productivity and 
greater participation in leisure activities compared to placebo patients as early as week 4, 
continuing until week 24. CZP-treated patients reported an average of 3.0-3.5 fewer days with no 
household work (compared to 1.0; p<0.05), 3.6-4.2 fewer days with reduced household 
productivity (compared to 1.8; p<0.05), and PsA interference productivity reduced by 2.3-3.0 
(compared to 0.8; p<0.05). Additionally, CZP patients also gained an average of 2.3-3.0 days per 
month for time with family or social activities (compared to 0.9 days; p<0.05). Table 3 
demonstrates the mean difference and confidence intervals. Notably, days with household work 
reduced by >50% had a mean difference of 3.9 and 3.4 days for CZP 200mg and CZP 400mg, 
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respectively with a confidence interval of 95% and p value <0.001. The rates of adverse events, 
serious adverse events, and infection were similar between CZP and placebo. The most common 
AEs were diarrhea and headache, with the most common infection being nasopharyngitis. Two 
deaths occurred during the first 24 weeks; one death in a patient taking CZP 200 caused by 
myocardial infarction and another death of unknown origin in a patient taking CZP 400. Both 
deaths were considered unrelated to study medication. Additionally, one patient receiving CZP 
400 reported non-invasive cervical carcinoma.  
Table 3: Improvements in productivity in the home at week 24. 
Productivity at home and 
daily activities over previous 
4 weeks 
CZP 200mg – Placebo Mean 
Diff (95% CI) (p value) 
CZP 400mg – Placebo Mean 
Diff (95% CI) 
Days with no household work 
due to arthritis 
-2.3 (-4.0 to -0.7) (0.007) -2.2 (-3.9 to -0.6) (0.010) 
Days with household work 
reduced by >50% 
-3.9 (-5.8 to -2.2) (<0.001) -3.4 (-5.3 to -1.5) (<0.001) 
Days missed of family, 
social, or leisure activities 
due to arthritis 
-1.7 (-3.1 to -0.5) (0.005) -1.8 (-3.2 to -0.6) (0.004) 
Days with outside help hired 
due to arthritis  
-1.2 (-2.4 to -0.3) (0.008) -0.4 (-1.7 to 1.0) (0.582) 
Rate of arthritis interference 
with household productivity 
-1.8 (-2.5 to -1.2) (<0.001) -1.5 (-2.1 to -0.8) (<0.001) 
 
 Torii et al5 studied PsA patients with at least moderate to severe plaque psoriasis for at 
least 6 months. A history of serious infection or active tuberculosis were part of the exclusion 
criteria due to the immune-suppressing effects of TNF- inhibitors and possible reactivation of 
tuberculosis.8 This phase III multicenter trial was conducted at 28 medical institutes in Japan. It 
was biphasic and consisted of induction phase through week 14 and a maintenance phase through 
week 78. The data presented was dichotomous, those reaching PASI 75 response and those who 
did not. Infliximab was administered over a period of 2 hours on day 0 and at weeks 2 and 6. The 
maintenance phase was an open label trial to evaluate the efficacy of long term management. In 
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this phase, infliximab was administered every 8 weeks. A total of 54 patients entered the 
induction phase. The discontinuation rate was 12.5% in the infliximab group, and 14.9% in the 
overall population, most commonly due to adverse side effects. Regarding safety and tolerability, 
there was only one serious adverse event and one adverse drug reaction in both groups with no 
clear difference. Serious infusion reaction occurred once in the INF group. Only 3 patients had 
treatment failure and 4 patients dropped out and were treated as “not improved.” The PASI 
response at week 10 was 68.6% in the infliximab group, compared with 0.0% in the placebo 
group (p<0.001). Improvements in PASI 75 rates continued in the maintenance phase through 
week 66. In the patients receiving placebo who were switched to INF at week 16, the PASI 75 
score improved immediately, with a PASI 75 response rate of 66.7% at week 26 (as 
demonstrated in figure 1). The absolute benefit increase (ABI) was 0.686 and the number of 
patients needed to treat (NNT) to achieve a PASI 75 response was 2 patients.  
 
Figure 1: Percent of patients achieving PASI 75 response from baseline through week 66.  
 
DISCUSSION 
 Psoriatic arthritis is a chronic inflammatory arthritis seen in 30% of patients with 
psoriasis. A substantial proportion of these patients will progress in disease severity until 
functional impairment, sometimes leading to work disability and loss of productivity with 
associated decreased quality of life.1 Current regimes have been less than ideal, and a novel 
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agent is needed to treat both the symptoms and severity of joint inflammation as well as psoriatic 
skin lesions. 
 Infliximab (Brand name: Remicade) is a chimeric monoclonal antibody that binds TNF- 
and thus reducing levels of TNF- in tissue of fluids of patients with psoriatic arthritis as well as 
other inflammatory diseases.9 It is also used to treat patients with ankylosing spondylitis, 
inflammatory bowel disease, and rheumatoid arthritis. FDA warnings for this drug include 
increased risk of serious infection, increased risk of cancer (specifically Lymphoma in children), 
and reactivation of latent tuberculosis.9 The cost for this drug is approximately $1400 for a 
100mg reconstituted solution.9 
 This systematic review analyzed three randomized control trials which demonstrated the 
effectiveness of infliximab and certolizumab pegol in the treatment of PsA.1,5,7 Atteno et al1 
showed that infliximab significantly reduces the number of tender and swollen joints as well as 
psoriasis severity which is reflected in their increased value of their own health assessment. 
Kavanagh et al7 found that patients treated with certolizumab pegol greatly affected the patient’s 
productivity in the home. Patients gained more days of productivity, experienced less 
interference from arthritis with their activities at home, and were able to spend more time in 
leisure activities or time with friends and family. Torii et al5 found that infliximab showed 
sustained improvement of joint and skin symptoms correlating with increase quality of life and is 
useful for the treatment of PsA. 
 Regarding limitations, Atteno et al1 only studied 100 patients which is a small sample 
size, and may not be indicative of the population at large. A significant limitation in the 
Kavanagh et al7 study was the use of Last Observation Carried Forward in the 10% of patients 
that were lost to follow-up to impute missing data. In 2012, the National Research Council’s 
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Panel on Handling Missing Data in Clinical Trials recommended against the use of this method 
due to demonstrated inaccuracies, and any data analysis using this method should be questioned 
for validity.10 Finally, a potential limitation in the Torii et al5 study is that the study took place 
across 28 medical institutes in Japan, outside of the oversight, standards, and regulations of the 
United States. 
CONCLUSION 
The evidence shows that TNF- inhibitors infliximab and certolizumab pegol are 
effective in treating adults with psoriatic arthritis as well as PsA patients with prior failure of 
DMARD therapy. They have been shown in these trials to effectively reduce symptoms of 
arthritis and psoriasis, and improve quality of life with minimal adverse events compared to 
control.1,5,7 Prompt treatment of PsA with TNF- inhibitors may impact the disease progression 
and joint destruction in patients with PsA. 
While these drugs have been shown to be efficacious, autoantibody formation to TNF- 
inhibitors during treatment is an area of concern. The presence of anti-nuclear antibodies and 
anti-double-stranded DNA antibodies have been seen and has been associated with autoimmune 
phenomena such as lupus-like syndrome or demyelination.12 Although the exact mechanism and 
clinical implications require clarification, reports have linked this autoantibody formation to 
undesirable clinical manifestations.12 Future research should determine the extent and prevalence 
of this phenomenon.  
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